drug development Archives

Comic-style illustration titled “The Fund-Raisers!” showing investors, a biotech innovation globe, a Forbion shield and laboratories, with a speech bubble announcing “2.6 billion raised.”

Forbion’s $2.6 Billion Biotech Raise Signals Smart Money Is Backing the Next Wave of Medicines -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. 2 days ago 334Views 0Likes

Two new funds, institutional backing and a pharmaceutical heavyweight give the European life sciences investor fresh capital to turn promising science into investable businesses. Biotechnology has never suffered from a shortage of ambitious ideas. Financing them is another matter. Forbion has just…

Comic-style illustration of Michael J. Fox pointing toward Parkinson’s research and clinical trial displays, surrounded by scientists, patients and investors, with upward arrows symbolizing progress and investor optimism.

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

by John F. Heerdink, Jr. 2 days ago 179Views 0Likes

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 450Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 181Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Illustration of a bullish investment landscape showing AI-powered ecommerce, healthcare innovation, cybersecurity and market growth. Robots manage online-shopping fulfillment around an ecommerce screen, clinicians and researchers work in a modern medical setting, and professionals point toward rising stock charts and upward arrows, with the phrases “AI Commerce,” “Healthcare” and “Stay Engaged.”

A Resilient Economy, AI Commerce & Healthcare Catalysts Give Many More Than One Reason to Stay Engaged -( $AMWL $AMZN $APPL $CRWD $GOOG $OKTA $PANW $PYPL $SER $SHOP $SMWB $XYZ $ZS )

by John F. Heerdink, Jr. September 14, 2026 428Views 0Likes

Many entered the week bracing for a Federal Reserve rate hike, yet the more constructive takeaway may be that policy makers still have room to choose patience. That possibility, alongside fresh evidence of AI-led ecommerce change, government-scale digital-health demand and advancing biotech milestones,…

Investor infographic illustrating Eli Lilly and Company (NYSE: LLY) investing up to $2.875 billion to acquire Merida Biosciences, linking Lilly’s headquarters and cash investment to Merida’s antibody-engineering candidates, precision immunology research, and projected future revenue growth.

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. September 1, 2026 252Views 0Likes

Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…

Eupraxia Pharmaceuticals: The Small‑Cap Biotech Quietly Seeking To Build a Billion‑Dollar Plus EoE Franchise -( $EPRX $IBB $XBI )

by Vista Partners LLC December 12, 2025 821Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX, $6.40, +1.59% today and +85.51% over the last year) is emerging as a standout small‑cap biotech, transforming a once‑niche GI indication and routine endoscopy visits into a compelling, scalable growth platform, underpinned by a mid‑teens price target from…

The Year of the Bispecific: Biotech’s Double-Edged Breakout -( $ARKG $IBB $XBI $RHBBY $AMGN $JNJ )

by Vista Partners LLC December 10, 2025 506Views 0Likes

If 2024 crowned weight-loss drugs the belle of the healthcare ball, 2025 belongs to the bispecific antibody. What began as a niche in immuno-oncology has evolved into biotech’s most competitive—and potentially lucrative—battleground, drawing fresh capital, dealmaking, and analyst optimism that borders on…

“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )

by John F. Heerdink, Jr. June 16, 2025 550Views 0Likes

In the bustling digital amphitheater of Tribe Public’s latest CEO Presentation, the question of the hour was as sharp as it was timely: “Is the beaten down biotech sector the smartest bet in today’s volatile market?” With a flourish of slides and…

Tag: drug development

Forbion’s $2.6 Billion Biotech Raise Signals Smart Money Is Backing the Next Wave of Medicines -( $IBB $LLY $XBI )

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

A Resilient Economy, AI Commerce & Healthcare Catalysts Give Many More Than One Reason to Stay Engaged -( $AMWL $AMZN $APPL $CRWD $GOOG $OKTA $PANW $PYPL $SER $SHOP $SMWB $XYZ $ZS )

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

Eupraxia Pharmaceuticals: The Small‑Cap Biotech Quietly Seeking To Build a Billion‑Dollar Plus EoE Franchise -( $EPRX $IBB $XBI )

The Year of the Bispecific: Biotech’s Double-Edged Breakout -( $ARKG $IBB $XBI $RHBBY $AMGN $JNJ )

“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )

Your Guide To Staying Informed In The Markets